A greater frequency of CCND1 amplifications is observed in ER-positive subsets of breast cancer patients, and a shorter DFS for the ER-positive subset of CCND1-amplified patients has been reported [31, 34, 38, 39, 41, 42]. This evidence concerns the gene ESR1 and breast carcinoma.